TD Cowen raised the firm’s price target on Elevance Health (ELV) to $400 from $380 and keeps a Buy rating on the shares. The firm said it is a Best Idea for 2026. Managed care continues to be a complicated investment landscape, but we see the company’s current 2026 EPS consensus as appropriate and a basis for growth.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health: Strategic Positioning and Stability Drive Buy Rating with $400 Price Target
- Trump Trade: White House postpones healthcare proposal after backlash
- Speaker Johnson warns House Republicans don’t want ACA subsidies, WSJ says
- White House postpones healthcare proposal after backlash, MS Now says
- White House expected to unveil extension of Obamacare subsidies, Politico says